Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript

·44 min read
Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript

At this time, I'd like to turn the conference over to Atabak Mokari. Today, we issued three press releases, one announcing the positive outcome of our 178 patients Phase 2 trial of relacorilant in combination with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. Second, announcing markedly decreased liver fat in patients in our Phase 2 trial of miricorilant as a potential treatment for nonalcoholic steatohepatitis or NASH, and the third, providing a clinical update and announcing our financial results for the first quarter.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting